Form 4: Cytokinetics EVP Fady Ibraham Malik Sells Shares to Cover Restricted Stock Unit Vesting
SEC Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 8,228 shares of common stock on March 6, 2025, to cover a transaction related to the vesting of restricted stock units.
Summary
- On March 6, 2025, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc., sold 8,228 shares of the company's common stock.
- The sale was executed at a price of $43.27 per share.
- The transaction was related to covering obligations associated with the vesting of restricted stock units.
- Following the transaction, Malik directly owns 105,394 shares of Cytokinetics Inc.
- The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to executive compensation and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine disclosure of an insider stock sale, likely related to compensation and tax obligations. It's common for executives to sell shares acquired through equity compensation.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it's a small percentage of the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of the stock sale transaction. |
| 03/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.